Having \u226520 percent increases in pTau-181 associated with increased A\u03b240\/42 levels and with central neurological symptoms<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Jan. 20, 2026 (HealthDay News) — Increased phosphorylated Tau-181 (pTau-181) levels are seen in association with neurological manifestations of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (Neurological PASC [N-PASC]) consistent with central damage, according to a study published in the January issue of eBioMedicine<\/em>.<\/p>\n Xiaohua Yang, from the World Trade Center Health Program at Stony Brook University in New York, and colleagues examined whether N-PASC is associated with changes in neurological biomarkers after COVID-19. Plasma samples were retrieved before and after COVID-19 onset among 227 essential workers who developed COVID-19 with N-PASC and were demographically matched with data from 227 controls who developed COVID-19 without N-PASC or who did not develop COVID-19 (124 and 103 participants, respectively).<\/p>\n The researchers found that N-PASC was only associated with higher total amyloid \u03b2 burden before onset of COVID-19 (area under receiver operating characteristic curve, 0.77). In participants who developed N-PASC, plasma pTau-181 levels increased by 59.3 percent following COVID-19 onset, and were worst among participants reporting central nervous symptoms persisting \u22651.5 years. Post-COVID-19 reductions in glial fibrillary acidic protein and neurofilament light chain were associated with peripheral symptoms of N-PASC, but not with increases in pTau-181. There was an association seen for having \u226520 percent increases in pTau-181 with increased amyloid \u03b240\/42 levels at follow-up and with central neurological symptoms such as persistent brain fog and loss of taste\/smell.<\/p>\n “This is one of the first studies to show that a virus may contribute to the development of abnormal tau production over time,” senior author Benjamin J. Luft, M.D., also with the World Trade Center Health Program, said in a statement.<\/p>\n